ROIVANT SCIENCES LTD. Interest Expense
ROIVANT SCIENCES LTD. (ROIV) reported Interest Expense of $13.40 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-09
- ROIVANT SCIENCES LTD. interest expense for the quarter ending 2024-06-30 was $13.40M, a 50.35% increase year-over-year.
- ROIVANT SCIENCES LTD. interest expense for the quarter ending 2024-03-31 was $7.17M, a 16.33% decline year-over-year.
- ROIVANT SCIENCES LTD. interest expense for the quarter ending 2023-12-31 was $9.44M, a 11.82% increase year-over-year.
- ROIVANT SCIENCES LTD. interest expense for the quarter ending 2023-09-30 was $9.25M, a 10.94% increase year-over-year.
- ROIVANT SCIENCES LTD. interest expense for fiscal 2024 was $34.78M, a 24.35% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. interest expense for fiscal 2023 was $27.97M, a 297.22% increase from fiscal 2022.
- ROIVANT SCIENCES LTD. interest expense for fiscal 2022 was $7.04M, a 150.66% increase from fiscal 2021.
- ROIVANT SCIENCES LTD. interest expense for fiscal 2021 was $2.81M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $13.40M 10-Q · filed 2024-08-09 | $20.57M derived: sum of 2 quarters · filed 2024-08-09 | $30.02M derived: sum of 3 quarters · filed 2024-08-09 | $39.27M derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-30 | $16.62M derived: sum of 2 quarters · filed 2024-05-30 | $25.87M derived: sum of 3 quarters · filed 2024-05-30 | $34.78M 10-K · filed 2024-05-30 |
| 2023-12-31 | $9.44M 10-Q · filed 2024-02-13 | $18.69M derived: sum of 2 quarters · filed 2024-02-13 | $27.60M 10-Q · filed 2024-02-13 | $36.18M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-09-30 | $9.25M 10-Q · filed 2023-11-13 | $18.16M 10-Q · filed 2023-11-13 | $26.73M derived: sum of 3 quarters · filed 2024-08-09 | $35.18M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-06-30 | $8.91M 10-Q · filed 2024-08-09 | $17.49M derived: sum of 2 quarters · filed 2024-08-09 | $25.93M derived: sum of 3 quarters · filed 2024-08-09 | $34.27M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-30 | $17.02M derived: sum of 2 quarters · filed 2024-05-30 | $25.36M derived: sum of 3 quarters · filed 2024-05-30 | $27.97M 10-K · filed 2024-05-30 |
| 2022-12-31 | $8.45M 10-Q · filed 2024-02-13 | $16.78M derived: sum of 2 quarters · filed 2024-02-13 | $19.39M 10-Q · filed 2024-02-13 | $20.87M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $8.34M 10-Q · filed 2023-11-13 | $10.95M 10-Q · filed 2023-11-13 | $12.42M derived: sum of 3 quarters · filed 2023-11-13 | $13.92M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.61M 10-Q · filed 2023-08-14 | $4.09M derived: sum of 2 quarters · filed 2023-08-14 | $5.59M derived: sum of 3 quarters · filed 2023-08-14 | $7.14M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $2.98M derived: sum of 2 quarters · filed 2023-06-28 | $4.53M derived: sum of 3 quarters · filed 2023-06-28 | $7.04M 10-K · filed 2023-06-28 |
| 2021-12-31 | $1.50M 10-Q · filed 2022-02-14 | $3.05M derived: sum of 2 quarters · filed 2022-02-14 | $5.57M 10-Q · filed 2022-02-14 | $6.24M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-09-30 | $1.55M 10-Q · filed 2021-11-15 | $4.07M 10-Q · filed 2021-11-15 | $4.74M derived: sum of 3 quarters · filed 2022-08-15 | $5.47M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-06-30 | $2.51M 10-Q · filed 2022-08-15 | $3.19M derived: sum of 2 quarters · filed 2022-08-15 | $3.92M derived: sum of 3 quarters · filed 2022-08-15 | $4.53M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $1.41M derived: sum of 2 quarters · filed 2022-06-28 | $2.02M derived: sum of 3 quarters · filed 2022-06-28 | $2.81M 10-K · filed 2022-06-28 |
| 2020-12-31 | $737.00K 10-Q · filed 2022-02-14 | $1.34M derived: sum of 2 quarters · filed 2022-02-14 | $2.14M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $608.00K 10-Q · filed 2021-11-15 | $1.40M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $791.00K 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |